Vertex CEO takes Morgan Stanley analyst to task at conference

Vertex Pharmaceuticals ($VRTX) CEO Matthew Emmens didn't stick with the script at yesterday's Morgan Stanley Global Healthcare Conference. Armed with stellar early sales figures for Vertex's new hep C drug Incivek, Emmens scolded the investment bank's own analyst David Friedman, accusing him of failing to understand the company. Report